ArticleObstetrics and gynecology2014
Trends in glyburide compared with insulin use for gestational diabetes treatment in the United States, 2000-2011.
Article in Obstetrics and gynecology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 143 citations in OpenAlex.
- American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022Guideline
- Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis.BMJ (Clinical research ed.) · 2015 · on this mapPooled it
- Pharmacodynamics of Glyburide, Metformin, and Glyburide/Metformin Combination Therapy in the Treatment of Gestational Diabetes Mellitus.Clinical pharmacology and therapeutics · 2020 · on this mapTrial
- Trial
- Glibenclamide and metfoRmin versus stAndard care in gEstational diabeteS (GRACES): a feasibility open label randomised trial.BMC pregnancy and childbirth · 2017Trial
- From Standard of Care to Emerging Innovations: Navigating the Evolution of Pharmacological Treatment of Gestational Diabetes.American journal of perinatology · 2025Review
- Changes in medication initiation and selection patterns for gestational diabetes management.BJOG : an international journal of obstetrics and gynaecology · 2024Article
- Prioritizing Variables for Observational Study Design using the Joint Variable Importance Plot.The American statistician · 2024Article
- Mental Health Within 24 Months After Delivery Among Women with Common Pregnancy Conditions.Journal of women's health (2002) · 2023Article
- Regulation of Placental Efflux Transporters during Pregnancy Complications.Drug metabolism and disposition: the biological fate of chemicals · 2022Review
- A Clinical Update on Gestational Diabetes Mellitus.Endocrine reviews · 2022Article
- Development and validation of prediction models for gestational diabetes treatment modality using supervised machine learning: a population-based cohort study.BMC medicine · 2022Article
- Association of Glyburide and Subcutaneous Insulin With Perinatal Complications Among Women With Gestational Diabetes.JAMA network open · 2022Article
- Changing patterns in medication prescription for gestational diabetes during a time of guideline change in the USA: a cross-sectional study.BJOG : an international journal of obstetrics and gynaecology · 2022 · on this mapArticle
- Correlates of Insulin Selection as a First-Line Pharmacological Treatment for Gestational Diabetes.American journal of perinatology · 2022Article
- Controversies in Gestational Diabetes.TouchREVIEWS in endocrinology · 2021Review
- Glycemic control and neonatal outcomes in women with gestational diabetes mellitus treated using glyburide, metformin, or insulin: a pairwise and network meta-analysis.BMC endocrine disorders · 2021Article
- Treatment of Gestational Diabetes Mellitus and Offspring Early Childhood Growth.The Journal of clinical endocrinology and metabolism · 2021Article
- Effects of Hydroxyl Group on the Interaction of Carboxylated Flavonoid Derivatives with S. Cerevisiae α-Glucosidase.Current computer-aided drug design · 2020Article
- The Use of Non-insulin Agents in Gestational Diabetes: Clinical Considerations in Tailoring Therapy.Current diabetes reports · 2019Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo describe trends and identify factors associated with choice of pharmacotherapy for gestational diabetes (GDM) from 2000-2011 using a healthcare claims database.
methodsThis was a retrospective cohort study of a large nationwide population of commercially insured women with GDM and pharmacy claims for glyburide or insulin before delivery, 2000-2011. We excluded women younger than 15 years or older than 50 years, those with prior noninsulin-dependent diabetes mellitus, or those who had multiple gestations. We estimated trends over time in the use of glyburide compared with insulin and prevalence ratios and 95% confidence intervals (CIs) for the association between covariates of interest and treatment with glyburide compared with insulin.
resultsWe identified 10,778 women with GDM treated with glyburide (n=5,873) or insulin (n=4,905). From 2000 to 2011, glyburide use increased from 7.4% to 64.5%, becoming the more common treatment in 2007. Women less likely to be treated with glyburide were those with metabolic syndrome (prevalence ratio 0.71, 95% CI 0.50-0.99), hyperandrogenism (prevalence ratio 0.77, 95% CI 0.62-0.97), polycystic ovarian syndrome (prevalence ratio 0.88, 95% CI 0.78-0.99), hypothyroidism (prevalence ratio 0.89, 95% CI 0.83-0.96), or undergoing infertility treatment (prevalence ratio 0.93, 95% CI 0.86-1.02). The probability of receiving glyburide decreased by 5% for every 10-year increase in maternal age (prevalence ratio 0.95, 95% CI 0.91-0.99). Among women prescribed with glyburide, 7.8% switched or augmented to a different drug class compared with 1.1% of insulin initiators.
conclusionGlyburide has replaced insulin as the more common pharmacotherapy for GDM over the past decade among those privately insured. Given its rapid uptake and the potential implications of suboptimal glucose control on maternal and neonatal health, robust evaluation of glyburide's relative effectiveness is warranted to inform treatment decisions for women with gestational diabetes. LEVEL OF EVIDENCE: II.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.